Financing type:  underwritten prospectus offering

Gross proceeds:  $115,055,200

Offering:  38.87 million listed shares

Offering price:  $2.96 per listed share

Overallotment option:  The underwriters may purchase a maximum of 5.07 million listed shares for overallotment purposes. As of April 27, 2026, such option has been fully exercised. All information presented herein includes such exercise.

Disclosure:  Refer to the short form base shelf prospectus dated May 23, 2025, the prospectus supplement dated April 22, 2026, and the company's news releases dated April 20, 2026, and April 27, 2026.